Floatz Rating
B60/100
Confidence
Indicative
Sponsor
M.D. Anderson Cancer Center
Modality
monoclonal_antibody
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
57High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07234487CT.gov Comparison of AVD + Low-Dose Nivolumab vs. PET-Adapted BEACOPP-like in Advanced cHL | — | Recruiting | — | — | — |
NCT06812858CT.gov PD-1 Inhibitors Maintenance for cHL Post-autoHCT | — | Recruiting | — | — | — |
NCT05675410CT.gov A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab | — | Recruiting | — | — | — |
NCT05723055CT.gov Evaluating Combination of Nivolumab and Axatilimab in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma | — | Active Not Recruiting | — | — | — |
NCT05272384CT.gov Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma | — | Recruiting | — | — | — |
NCT05255601CT.gov A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma | — | Completed | — | — | — |
NCT05352828CT.gov Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy | — | Active Not Recruiting | — | — | — |
NCT05253495CT.gov Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma | — | Recruiting | — | — | — |
NCT04938232CT.gov Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL | — | Active Not Recruiting | — | — | — |
NCT04866654CT.gov Radiation Free Chemotherapy for Early Hodgkin Lymphoma | — | Recruiting | — | — | — |
Show 21 more trialsShow fewer
NCT03878524CT.gov Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | — | Terminated | — | — | — |
NCT04134325CT.gov Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma | — | Active Not Recruiting | — | — | — |
NCT03907488CT.gov Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma | — | Active Not Recruiting | — | — | — |
NCT03843294CT.gov Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for Lymphoma | — | Active Not Recruiting | — | — | — |
NCT03646123CT.gov Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma | — | Terminated | — | — | — |
NCT03712202CT.gov Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma | — | Active Not Recruiting | — | — | — |
NCT03681561CT.gov Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma | — | Recruiting | — | — | — |
NCT03432741CT.gov Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer | — | Terminated | — | — | — |
NCT03233347CT.gov Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma | — | Active Not Recruiting | — | — | — |
NCT03343665CT.gov Treatment With Nivolumab at the Fixed Dose 40 mg (Nivo40) in Patients With Relapsed/Refractory Hodgkins Lymphoma | — | Completed | — | — | — |
NCT03138499CT.gov A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant, | — | Terminated | — | — | — |
NCT03057795CT.gov Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphoma | — | Active Not Recruiting | — | — | — |
NCT02927769CT.gov A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment | — | Completed | — | — | — |
NCT02758717CT.gov Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma | — | Active Not Recruiting | — | — | — |
NCT02973113CT.gov Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE) | — | Completed | — | — | — |
NCT02572167CT.gov A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma | — | Completed | — | — | — |
NCT02304458CT.gov Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas | — | Completed | — | — | — |
NCT01822509CT.gov Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant | — | Completed | — | — | — |
NCT01703949CT.gov Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma | — | Active Not Recruiting | — | — | — |
NCT01716806CT.gov A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) | — | Completed | — | — | — |
NCT01592370CT.gov An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hodgkins Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Nivolumab (this asset) | M.D. Anderson Cancer Center | P3 | B · 60 |
| Carboplatin | St. Petersburg State Pavlov Medical University | P2 | BBB |
| Camustine | VIVUS LLC | P2 | BBB |
| Everolimus | OHSU Knight Cancer Institute | P2 | BBB |
| Isocyclophosphamide | St. Petersburg State Pavlov Medical University | P3 | BBB |
| Cyclosporin A | City of Hope Medical Center | P3 | BBB |
| Vincristine Sulfate | National Cancer Institute (NCI) | P3 | BBB |
| Vinorelbine Ditartrate | Michael Spinner, MD | P3 | BBB |
| Vinblastine | M.D. Anderson Cancer Center | P4 | BBB |
+42 more in the Hodgkins Lymphoma cohort
Other indications for Nivolumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Renal Carcinoma | — | P4 | BBB · 72 |
| Metastatic Melanoma | — | P4 | BB · 70 |
| Non-Small Cell Lung Carcinoma | — | P4 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Nivolumab in Hodgkins Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/nivolumab-hodgkins-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →